Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Korro Bio, Inc. (KRRO)

Korro Bio doses first cohort in Phase 1/2 ANCHOR trial of KRRO-121

Neutral Impact 3 of 5 product/contract Written later

Korro Bio said it has dosed the first cohort of participants in the ANCHOR Phase 1/2 clinical trial of KRRO-121, a treatment in development for hyperammonemia in urea cycle disorders and hepatic encephalopathy. The filing describes a clinical milestone in an early-stage program and contains no financial results, guidance, or changes to the company's financing or management.

Key points

  • First cohort of healthy volunteers dosed with a single 2mg/kg dose in Australia
  • Dosing of urea cycle disorder patients expected to start in the first half of 2027
  • Interim readout expected in the second half of 2027

The filing

CompanyKorro Bio, Inc. (KRRO)
Form8-K, current report
Filed with the SECOct 5, 2026, 4:10 PM ET
Accession number0001193125-26-414118

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.